Skip to content
Omigapil
Omigapil is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOMIGAPIL
INNomigapil
Description
CGP-3466 is a dibenzooxepine.
Classification
Small molecule
Drug classneuronal apoptosis inhibitors; glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C#CCN(C)CC1=Cc2ccccc2Oc2ccccc21
Identifiers
PDB—
CAS-ID181296-84-4
RxCUI—
ChEMBL IDCHEMBL1232111
ChEBI ID41778
PubChem CID6419718
DrugBankDB12879
UNII ID5V14HD0N4Q (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 73 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details